[HTML][HTML] Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non–small-cell lung cancer

C Roach, N Zhang, E Corigliano… - Applied …, 2016 - journals.lww.com
A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-
cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC).
This automated IHC assay has been analytically verified and validated using Dako's
autostainer Link 48 and 22C3 mouse anti-PD-L1 monoclonal antibody to detect the PD-L1
expression in formalin-fixed paraffin-embedded human tumor tissue specimens. The PD-L1
22C3 IHC assay was optimized for high sensitivity and specificity. Repeatability and …